PMID- 37510700
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230801
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Electronic)
IS  - 2077-0383 (Linking)
VI  - 12
IP  - 14
DP  - 2023 Jul 10
TI  - Drug Retention Rates and the Safety of Janus Kinase Inhibitors in Elderly 
      Patients with Rheumatoid Arthritis.
LID - 10.3390/jcm12144585 [doi]
LID - 4585
AB  - BACKGROUND: We examined the real-world drug retention rate and safety data of 
      Janus kinase inhibitors (JAKis) in elderly patients with rheumatoid arthritis 
      (RA). METHODS: This study enrolled 133 RA patients (>/=65 years) with sufficient 
      clinical data who were initiated with JAKis during the study period. These 
      patients were divided into two groups: the very elderly group (>/= 75 years) and 
      the elderly group (65 </= years < 75). The drug retention rates of JAKis were 
      compared using Kaplan-Meier curves. RESULTS: The discontinuation rates of JAKis 
      were as follows: lack of effectiveness 27 (20.3%), adverse events (AEs) 29 
      (21.8%), and remission 2 (1.5%). There was no significant difference in the 
      overall drug retention rate between the very elderly group (>/=75 years) and the 
      elderly group. Furthermore, the overall drug retention rates of JAKis were not 
      affected by gender, methotrexate use, and anti-citrullinated protein/peptide 
      antibody (ACPA) status. The discontinuation rates of JAKis due to AEs were 
      comparable both in the very elderly group (>/=75 years) and the elderly group (65 </= 
      years < 75). Whereas chronic lung disease and hypoalbuminemia were independently 
      associated with discontinuation rates due to AEs, the overall drug retention 
      rates were significantly lower in patients treated with the approved dose of 
      JAKis than in those treated with a reduced or tapered dose. CONCLUSIONS: Our 
      results suggest that the overall drug retention rate of JAKis in very elderly 
      patients (>/=75 years) was comparable with that in elderly patients (65 </= years < 
      75). The discontinuation rates of JAKis due to AEs were also comparable both in 
      very elderly group patients and elderly patients.
FAU - Temmoku, Jumpei
AU  - Temmoku J
AD  - Department of Rheumatology, Fukushima Medical University School of Medicine, 1 
      Hikarigaoka, Fukushima 960-1295, Fukushima, Japan.
FAU - Miyata, Masayuki
AU  - Miyata M
AD  - Department of Rheumatology, Jananese Red Cross Fukushima Hospital, Yashima 7-7, 
      Fukushima 963-8558, Fukushima, Japan.
FAU - Suzuki, Eiji
AU  - Suzuki E
AD  - Department of Rheumatology, Ohta-Nishinouchi Hospital, 2-5-20 Nishinouchi, 
      Koriyama 963-8558, Fukushima, Japan.
FAU - Sumichika, Yuya
AU  - Sumichika Y
AD  - Department of Rheumatology, Fukushima Medical University School of Medicine, 1 
      Hikarigaoka, Fukushima 960-1295, Fukushima, Japan.
FAU - Saito, Kenji
AU  - Saito K
AD  - Department of Rheumatology, Fukushima Medical University School of Medicine, 1 
      Hikarigaoka, Fukushima 960-1295, Fukushima, Japan.
FAU - Yoshida, Shuhei
AU  - Yoshida S
AUID- ORCID: 0000-0001-5123-3136
AD  - Department of Rheumatology, Fukushima Medical University School of Medicine, 1 
      Hikarigaoka, Fukushima 960-1295, Fukushima, Japan.
FAU - Matsumoto, Haruki
AU  - Matsumoto H
AD  - Department of Rheumatology, Fukushima Medical University School of Medicine, 1 
      Hikarigaoka, Fukushima 960-1295, Fukushima, Japan.
FAU - Fujita, Yuya
AU  - Fujita Y
AUID- ORCID: 0000-0002-3936-3007
AD  - Department of Rheumatology, Fukushima Medical University School of Medicine, 1 
      Hikarigaoka, Fukushima 960-1295, Fukushima, Japan.
FAU - Matsuoka, Naoki
AU  - Matsuoka N
AD  - Department of Rheumatology, Fukushima Medical University School of Medicine, 1 
      Hikarigaoka, Fukushima 960-1295, Fukushima, Japan.
FAU - Asano, Tomoyuki
AU  - Asano T
AD  - Department of Rheumatology, Fukushima Medical University School of Medicine, 1 
      Hikarigaoka, Fukushima 960-1295, Fukushima, Japan.
FAU - Sato, Shuzo
AU  - Sato S
AUID- ORCID: 0000-0002-8110-8261
AD  - Department of Rheumatology, Fukushima Medical University School of Medicine, 1 
      Hikarigaoka, Fukushima 960-1295, Fukushima, Japan.
FAU - Migita, Kiyoshi
AU  - Migita K
AD  - Department of Rheumatology, Fukushima Medical University School of Medicine, 1 
      Hikarigaoka, Fukushima 960-1295, Fukushima, Japan.
LA  - eng
PT  - Journal Article
DEP - 20230710
PL  - Switzerland
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC10380728
OTO - NOTNLM
OT  - adverse events
OT  - drug retention rate
OT  - elderly patient
OT  - janus kinase inhibitor
OT  - safety
COIS- The authors declare no conflict of interest.
EDAT- 2023/07/29 11:44
MHDA- 2023/07/29 11:45
PMCR- 2023/07/10
CRDT- 2023/07/29 01:19
PHST- 2023/05/18 00:00 [received]
PHST- 2023/06/29 00:00 [revised]
PHST- 2023/07/04 00:00 [accepted]
PHST- 2023/07/29 11:45 [medline]
PHST- 2023/07/29 11:44 [pubmed]
PHST- 2023/07/29 01:19 [entrez]
PHST- 2023/07/10 00:00 [pmc-release]
AID - jcm12144585 [pii]
AID - jcm-12-04585 [pii]
AID - 10.3390/jcm12144585 [doi]
PST - epublish
SO  - J Clin Med. 2023 Jul 10;12(14):4585. doi: 10.3390/jcm12144585.